Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I–II study

The aim of this study was to evaluate feasibility and toxicity of escalating doses of epirubicin and paclitaxel plus fixed dose of etoposide and to define the activity of the triplet in extensive disease small-cell lung cancer. Thirteen patients entered the phase I study: the maximum tolerated doses...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Tibaldi, C, Prochilo, T, Russo, F, Pennucci, M C, Del Freo, A, Innocenti, F, Fabbri, A, Falcone, A, Conte, P F, Baldini, E
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2006
Teme:
Clinical Study
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361402/
https://ncbi.nlm.nih.gov/pubmed/16622468
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603074
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items